Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials

References

• Fox RI. Sjögren’s syndrome. Lancet. 2005;366(9482):321–331.
   PubMed Web of Science ®Google Scholar
• Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary sjögren’s syndrome: a consensus and data‐driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35–45. DOI:10.1002/art.39859
   PubMed Web of Science ®Google Scholar
• Jousse‐joulin S, Gatineau F, Baldini C, et al. Weight of salivary gland ultrasonography compared to other items of the 2016 ACR/EULAR classification criteria for primary Sjögren’s syndrome. J Intern Med. 2020;287(2):180–188. DOI:10.1111/joim.12992
   PubMed Web of Science ®Google Scholar
• Rasmussen A, Radfar L, Lewis D, et al. Previous diagnosis of Sjögren’s syndrome as rheumatoid arthritis or systemic lupus erythematosus. Rheumatology. 2016;55(7):1195–1201. DOI:10.1093/rheumatology/kew023
   PubMed Web of Science ®Google Scholar
• Fox RI, Fox CM. Sjögren syndrome: why do clinical trials fail? Rheum Dis Clin. 2016;42(3):519–530.
   PubMed Web of Science ®Google Scholar
• Löfgren CD, Isberg P-E, Christersson C. Screening for oral dryness in relation to salivary flow rate addresses the need for functional tests of saliva. Oral Health Prev Dent. 2010;8:243–252.
   PubMed Web of Science ®Google Scholar
• Nichols K K, Nichols J J, MPH M, et al. The Lack of Association Between Signs and Symptoms in Patients With Dry Eye Disease. Cornea. 2004;23(8);762–770. DOI:10.1097/01.ico.0000133997.07144.9e
   PubMed Web of Science ®Google Scholar
• Ryu O, Atkinson J, Hoehn G, et al. Identification of parotid salivary biomarkers in Sjögren’s syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology. 2006;45(9):1077–1086. DOI:10.1093/rheumatology/kei212
   PubMed Web of Science ®Google Scholar
• Kalk W, Vissink A, Spijkervet F, et al. Sialometry and sialochemistry: diagnostic tools for Sjögren’s syndrome. Ann Rheumatic Dis. 2001;60(12):1110–1116. DOI:10.1136/ard.60.12.1110
   PubMed Web of Science ®Google Scholar
• Akpek EK, Wu HY, Karakus S, et al. Differential diagnosis of Sjögren versus non-Sjögren dry eye through tear film biomarkers. Cornea. 2020;39(8):991–997. DOI:10.1097/ICO.0000000000002299
   PubMed Web of Science ®Google Scholar
• McCoy SS, Woodham M, Bartels CM, et al. Symptom-based cluster analysis categorizes sjögren’s disease subtypes: an international cohort study highlighting disease severity and treatment discordance. Arthritis Rheumatol. 2022;74(9):1569–1579. DOI:10.1002/art.42238
   PubMed Web of Science ®Google Scholar
• Tarn JR, Howard-Tripp N, Lendrem DW, et al. Symptom-based stratification of patients with primary sjögren’s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol. 2019;1(2):e85–94. DOI:10.1016/S2665-9913(19)30042-6
   PubMedGoogle Scholar
• Verstappen GM, Pringle S, Bootsma H, et al. Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. Nat Rev Rheumatol. 2021;17(6):333–348. DOI:10.1038/s41584-021-00605-2
   PubMed Web of Science ®Google Scholar
• Ridgewell D, Thalayasingam N, Ng W-F. Sjögren’s syndrome: shedding light on emerging and key drug targets. Expert Opin Ther Targets. 2022;26(10):1–14.
   PubMed Web of Science ®Google Scholar
• Verstappen GM, Gao L, Pringle S, et al. The transcriptome of paired major and minor salivary gland tissue in patients with primary Sjögren’s syndrome. Front Immunol. 2021;12:681941.
   PubMed Web of Science ®Google Scholar
• Mingueneau M, Boudaoud S, Haskett S, et al. Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren’s signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol. 2016 Jun;137(6):1809–1821.e12.
   PubMed Web of Science ®Google Scholar
• James JA, Guthridge JM, Chen H, et al. Unique Sjögren’s syndrome patient subsets defined by molecular features. Rheumatology (Oxford). 2020 Apr 1;59(4):860–868. DOI:10.1093/rheumatology/kez335
   PubMed Web of Science ®Google Scholar
• Bodewes IL, Al-Ali S, van Helden-Meeuwsen CG, et al. Systemic interferon type I and type II signatures in primary Sjögren’s syndrome reveal differences in biological disease activity. Rheumatology. 2018;57(5):921–930. DOI:10.1093/rheumatology/kex490
   PubMed Web of Science ®Google Scholar
• Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheumatic Dis. 2016;75(2):382–389. DOI:10.1136/annrheumdis-2014-206008
   PubMed Web of Science ®Google Scholar
• Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Ofimmunol Res. 2014;2014:1–8.
   Web of Science ®Google Scholar
• Lee JJ, Park YJ, Park M, et al. Longitudinal analysis of symptom-based clustering in patients with primary Sjogren’s syndrome: a prospective cohort study with a 5-year follow-up period. J Transl Med. 2021;19(1):1–8. DOI:10.1186/s12967-021-03051-6
   PubMed Web of Science ®Google Scholar
• Dev NWS, Seror R, Baron G, et al. Development and preliminary validation of the Sjogren’s tool for assessing response (STAR): a consensual composite score for assessing treatment effect in primary Sjogren’s syndrome. Ann Rheumatic Dis. 2022;81:189–190.
   Google Scholar
• Bootsma H, Arends S, de Wolff L, et al. POS0193 EVALUATION of CRESS in the PHASE 2 RANDOMISED PLACEBO-CONTROLLED STUDY of SEQUENTIAL BELIMUMAB/RITUXIMAB ADMINISTRATION in PATIENTS with PRIMARY SJÖGREN’S SYNDROME. Annals of Rheumatic Disease. 2022.
   Google Scholar
• Segal B, Bowman SJ, Fox PC, et al. Primary Sjögren’s syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes. 2009;7(1):1–9. DOI:10.1186/1477-7525-7-46
   PubMedGoogle Scholar
• Miyamoto ST, Valim V, Fisher BA. Health-related quality of life and costs in Sjögren’s syndrome. Rheumatology. 2021;60(6):2588–2601.
   PubMed Web of Science ®Google Scholar
• Lee T-Y, Slejko JF, Davies-Teye BB, et al. Economic burden of interstitial lung disease in a commercially insured population with Sjögren syndrome in the United States. J Manag Care Spec Pharm. 2022;28(7):786–794. DOI:10.18553/jmcp.2022.28.7.786
   PubMed Web of Science ®Google Scholar
• Callaghan R, Prabu A, Allan R, et al. Direct healthcare costs and predictors of costs in patients with primary Sjögren’s syndrome. Rheumatology. 2007;46(1):105–111. DOI:10.1093/rheumatology/kel155
   PubMed Web of Science ®Google Scholar
• Bowman SJ, Pierre YS, Sutcliffe N, et al. Estimating indirect costs in primary Sjögren’s syndrome. J Rheumatol. 2010;37(5):1010–1015. DOI:10.3899/jrheum.090734
   PubMed Web of Science ®Google Scholar
• Sivakumar GK, Patel J, Malvankar-Mehta MS, et al. Work productivity among Sjögren’s syndrome and non-Sjögren’s dry eye patients: a systematic review and meta-analysis. Eye. 2021;35(12):3243–3257. DOI:10.1038/s41433-020-01282-3
   PubMed Web of Science ®Google Scholar
• Koh S, Maeda N, Hori Y, et al. Effects of Suppression of Blinking on Quality of Vision in Borderline Cases of Evaporative Dry Eye. Cornea. 2008;27(3):275–278. DOI:10.1097/ICO.0b013e31815be9c8
   PubMed Web of Science ®Google Scholar
• Bejarano MV, Romanini F, Pellet AC, et al. Work productivity and activity impairment in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2021;39(6):S93–99. DOI:10.55563/clinexprheumatol/6rd9mr
   PubMed Web of Science ®Google Scholar
• W-F N, Bowman SJ, Griffiths B. United kingdom primary sjögren’s syndrome registry— a united effort to tackle an orphan rheumatic disease. Rheumatology. 2011;50(1):32–39.
   PubMed Web of Science ®Google Scholar
• Symmons D, Ng WF, Bowman SJ, et al. United kingdom primary sjögren’s syndrome registry-a united effort to tackle an orphan rheumatic disease. Rheumatology. 2011;50(1):32–39. DOI:10.1093/rheumatology/keq240
   PubMed Web of Science ®Google Scholar
• Gao M, Zhao L, Liang R, et al. Evaluation of the efficacy and safety of topical 0.05% cyclosporine eye drops (II) in the treatment of dry eye associated with primary Sjögren’s syndrome. Ocul Immunol Inflamm. 2022;1–7.
   Web of Science ®Google Scholar
• Doctor MB, Basu S. Lacrimal gland insufficiency in aqueous deficiency dry eye disease: recent advances in pathogenesis, diagnosis, and treatment. Semin Ophthalmol. 2022;37(7–8):801–812. Taylor & Francis. DOI:10.1080/08820538.2022.2075706
   PubMed Web of Science ®Google Scholar
• Eom Y, Song JS, Kim HM. Effectiveness of topical cyclosporin a 0.1%, diquafosol tetrasodium 3%, and their combination, in dry eye disease. J Ocul Pharmacol Ther. 2022;38(10):682–694.
   PubMed Web of Science ®Google Scholar
• Michelson PE, Fox RI. Overview of management of dry eye associated with Sjögren’s syndrome. Sjögren’s Syndrome: Springer; 2011. p. 179–201.
   Google Scholar
• Chrcanovic B, Kisch J, Wennerberg A, et al. Dental implants in patients with Sjögren’s syndrome: a case series and a systematic review. International Journal of Oral and Maxillofacial Surgery. 2019;48(9):1250–1259. DOI:10.1016/j.ijom.2019.02.005
   PubMed Web of Science ®Google Scholar
• Dawson L, Caulfield V, Stanbury J, et al. Hydroxychloroquine therapy in patients with primary Sjögren’s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology. 2005;44(4):449–455. DOI:10.1093/rheumatology/keh506
   PubMed Web of Science ®Google Scholar
• Hashimoto N, Nakazawa T, Iwasaki T, et al. POS0706 LONG-TERM HYDROXYCHLOROQUINE TREATMENT IMPROVES ESSPRI and ESSDAI in PATIENTS with PRIMARY SJOGREN’S SYNDROME. Annals of Rheumatic disease. 2022.
   PubMedGoogle Scholar
• Wang S-Q, Zhang L-W, Wei P, et al. Is hydroxychloroquine effective in treating primary Sjogren’s syndrome: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2017;18(1):1–13. DOI:10.1186/s12891-017-1543-z
   PubMedGoogle Scholar
• Gottenberg J-E, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA. 2014;312(3):249–258. DOI:10.1001/jama.2014.7682
   PubMed Web of Science ®Google Scholar
• Rynes RI. Hydroxychloroquine treatment of rheumatoid arthritis. Am j med. 1988;85(4):18–22.
   PubMedGoogle Scholar
• Manoussakis M, Moutsopoulos H. Antimalarials in Sjogren’s syndrome-the greek experience. Lupus. 1996;5(1_suppl):28–30.
   Google Scholar
• Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136(3):419–431. DOI:10.1016/j.pain.2008.02.027
   PubMed Web of Science ®Google Scholar
• Van Woerkom J, Kruize A, Geenen R, et al. Safety and efficacy of leflunomide in primary Sjögren’s syndrome: a phase II pilot study. Ann Rheumatic Dis. 2007;66(8):1026–1032. DOI:10.1136/ard.2006.060905
   PubMed Web of Science ®Google Scholar
• Pepple S, Arnold J, Vital EM, et al. P245 identifying predictors of short-term response to rituximab in extra-glandular primary Sjogren’s syndrome. Rheumatology. 2022;61(Supplement_1):keac133. 244. DOI:10.1093/rheumatology/keac133.244
   Google Scholar
• Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheumatic Dis. 2008;67(11):1541–1544. DOI:10.1136/ard.2007.083865
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Tolerance and Efficacy of Rituximab in Primary Sjogren Syndrome (Tears): results of a randomized controlled trial [conference paper]. Ann Rheum Dis. 2012 Jun;71:75.
   PubMed Web of Science ®Google Scholar
• Fisher BA, Everett CC, Rout J, et al. Effect of rituximab on a salivary gland ultrasound score in primary Sjögren’s syndrome: results of the TRACTISS randomised double-blind multicentre substudy. Ann Rheum Dis. 2018 Mar;77(3):412–416.
   PubMed Web of Science ®Google Scholar
• Mariette X, Barone F, Baldini C, et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome. JCI Insight. 2022;7(23).
   PubMed Web of Science ®Google Scholar
• de Wolff L, van Nimwegen JF, Mossel E, et al. editors. Long-term abatacept treatment for 48 weeks in patients with primary Sjögren’s syndrome: the open-label extension phase of the ASAP-III trial. Semin Arthritis Rheum. 2022;53:151955. Elsevier. DOI:10.1016/j.semarthrit.2022.151955
   PubMed Web of Science ®Google Scholar
• Endocrinopathy TSsS RI. Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren’s syndrome associated with rheumatoid arthritis: findings from an open-label. 2022.
   Google Scholar
• Chowdhury F. The longitudinal effects of rituximab in the Trial for Anti-B Cell Therapy in Primary Sjögren’s Syndrome (TRACTISS). 2022.
   Google Scholar
• Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren’s syndrome: a twelve‐week randomized, double‐blind, placebo‐controlled pilot clinical trial. Arthritis Rheumatol. 2004;50(7):2240–2245. DOI:10.1002/art.20299
   PubMedGoogle Scholar
• Felten R, Devauchelle-Pensec V, Seror R, et al. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheumatic Dis. 2021;80(3):329–338. DOI:10.1136/annrheumdis-2020-218467
   PubMed Web of Science ®Google Scholar
• Verstappen GM, van Nimwegen JF, Vissink A, et al. The value of rituximab treatment in primary Sjögren’s syndrome. Clin Immunol. 2017;182:62–71.
   PubMed Web of Science ®Google Scholar
• Bowman SJ, Everett CC, O’Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s syndrome. Arthritis Rheumatol. 2017 Jul;69(7):1440–1450.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Fabris M, Salvin S, et al. Controversies on rituximab therapy in sjögren syndrome-associated lymphoproliferation. Int J Rheumatol. 2009;2009. DOI:10.1155/2009/424935
   PubMedGoogle Scholar
• Chen YH, Wang XY, Jin X, et al. Rituximab therapy for primary Sjögren’s syndrome. Front Pharmacol. 2021;12:731122.
   PubMed Web of Science ®Google Scholar
• Merino‐vico A, Frazzei G, van Hamburg JP, et al. Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches. Eur J Immunol. 2023 Jan;53(1):e2149675.
   Web of Science ®Google Scholar
• Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study. Ann Rheumatic Dis. 2015;74(3):526–531. DOI:10.1136/annrheumdis-2013-203991
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. Rheumatology. 2015;54(12):2249–2256. DOI:10.1093/rheumatology/kev257
   PubMed Web of Science ®Google Scholar
• Bowman SJ, Fox R, Dörner T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren’s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022;399(10320):161–171. DOI:10.1016/S0140-6736(21)02251-0
   PubMed Web of Science ®Google Scholar
• Baer AN, Gottenberg JE, St Clair EW, et al. Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial. Ann Rheum Dis. 2021 Mar;80(3):339–348.
   PubMed Web of Science ®Google Scholar
• Fisher BA, Szanto A, W-F N, et al. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren’s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. Lancet Rheumatol. 2020;2(3):e142–152. DOI:10.1016/S2665-9913(19)30135-3
   Google Scholar
• Karnell JL, Rieder SA, Ettinger R, et al. Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond. Adv Drug Delivery Rev. 2019;141:92–103.
   PubMed Web of Science ®Google Scholar
• van der Heijden E HM, Hartgring S AY, Kruize A A, et al. Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sjögren’s syndrome. Expert Review of Clinical Immunology. 2019;15(7):801–808. DOI:10.1080/1744666X.2019.1624527
   PubMed Web of Science ®Google Scholar
• Norheim KB, Harboe E, Gøransson LG, et al. Interleukin-1 inhibition and fatigue in primary Sjögren’s syndrome–a double blind, randomised clinical trial. PLoS ONE. 2012;7(1):e30123. DOI:10.1371/journal.pone.0030123
   PubMed Web of Science ®Google Scholar
• Chiche L, Cornec D. Mysterious uncoupled clinical symptoms and interferon signature in Sjögren’s syndrome: limitations of current approaches for unravelling complexity? Rheumatology. 2020;59(1):5–6.
   PubMed Web of Science ®Google Scholar
• Fisher B, Barone F, Jobling K, et al. OP0202 effect of RSLV-132 on fatigue in patients with primary Sjögren’s syndrome–results of aphase II randomised, double-blind, placebo-controlled, proof of concept study. Annals of Rheumatic disease. 2019;78:177.
   Google Scholar
• Bai W, Yang F, Xu H, et al. A multi-center, prospective, open-label, randomized study to explore efficacy and safety of baricitinib in active primary sjogren’s syndrome patients. Trials. . 2023 Feb 15;24(1):112.
   Google Scholar
• Price E, Bombardieri M, Kivitz A, et al. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study. Rheumatology. 2022;61(12):4797–4808. DOI:10.1093/rheumatology/keac167
   PubMed Web of Science ®Google Scholar
• Ringheim GE, Wampole M, Oberoi K. Bruton’s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. Front Immunol. 2021;12:662223.
   PubMed Web of Science ®Google Scholar
• Watterson SH, Liu Q, Beaudoin Bertrand M, et al. Discovery of branebrutinib (BMS-986195): astrategy for identifying ahighly potent and selective covalent inhibitor providing rapid invivo inactivation of bruton’s tyrosine kinase (BTK). J Med Chem. 2019 Apr 11;62(7):3228–3250. DOI:10.1021/acs.jmedchem.9b00167. Epub 2019 Mar 29.
   Web of Science ®Google Scholar
• Nair JJ, Singh TP. Sjogren’s syndrome: review of the aetiology, pathophysiology & potential therapeutic interventions. J Clin Exp Dent. 2017;9(4):e584.
   PubMedGoogle Scholar
• Zhang H, Gao D, Ji L, et al.Ab0030 the biological function and mechanism exploration of taci in sjogren’s syndrome. Annals of the Rheumatic Diseases. 2022;81:1149–1150.
   Google Scholar
• Vugmeyster Y, Seshasayee D, Chang W, et al. A soluble BAFF antagonist, BR3-fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathol. 2006;168(2):476–489. DOI:10.2353/ajpath.2006.050600
   PubMed Web of Science ®Google Scholar
• Clair EW S, Baer AN, Wei C, et al. Clinical efficacy and safety of baminercept, a lymphotoxin β receptor fusion protein, in primary sjögren’s syndrome: results from a phase II randomized, double‐Blind, placebo‐Controlled trial. Arthritis Rheumatol. 2018;70(9):1470–1480. DOI:10.1002/art.40513
   PubMed Web of Science ®Google Scholar
• Seror R, Nocturne G, Mariette X. Current and future therapies for primary sjögrensyndrome. Nat Rev Rheumatol. 2021;17(8):475–486.
   PubMed Web of Science ®Google Scholar
• Mariette X, Bombardieri M, Alevizos I, et al., editors. A phase 2a study of MEDI5872 (AMG557), a fully human anti-ICOS ligand monoclonal antibody in patients with primary sjogren’s syndrome. Arthritis Rheumatol. 2019;71(suppl 10). Accessed May 3, 2023. https://acrabstracts.org/abstract/a-phase-2a-study-of-medi5872-amg557-a-fully-human-anti-icos-ligand-monoclonal-antibody-in-patients-with-primary-sjogrens-syndrome
   Google Scholar
• Chatzis L, Vlachoyiannopoulos PG, Tzioufas AG, et al. New frontiers in precision medicine for sjogren’s syndrome. Expert Rev Clin Immunol. 2021;17(2):127–141. DOI:10.1080/1744666X.2021.1879641
   PubMed Web of Science ®Google Scholar
• Ritter J, Chen Y, Stefanski L, et al. Current and future treatment in primary sjögren’s syndrome – a still challenging development. Joint Bone Spine. 2022;89(6):105406. DOI:10.1016/j.jbspin.2022.105406
   PubMed Web of Science ®Google Scholar
• Chen H, Qi X, Li Y, et al. Iguratimod treatment reduces disease activity in early primary sjögren’s syndrome: an open-label pilot study. Mod Rheumatol. 2021;31(2):394–398. DOI:10.1080/14397595.2020.1789335
   PubMed Web of Science ®Google Scholar
• Smyth P, Sasiwachirangkul J, Williams R, et al. Cathepsin S (CTSS) activity in health and disease-A treasure trove of untapped clinical potential. Mol Aspect Med. 2022;88:101106.
   PubMed Web of Science ®Google Scholar
• Dörner T, Zeher M, Laessing U, et al. OP0250 A randomised, double-blind study to assess the safety, tolerability and preliminary efficacy of leniolisib (CDZ173) in patients with primary sjÖgren’s syndrome. Annals of the Rheumatic Diseases. 2018;77:174.
   PubMed Web of Science ®Google Scholar
• Juarez M, Diaz N, Johnston GI, et al. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary sjögren’s syndrome. Rheumatology. 2021;60(3):1364–1375. DOI:10.1093/rheumatology/keaa410
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Moutsopoulos HM. Sjögren’s syndrome: old and new therapeutic targets. J Autoimmun. 2020;110:102364.
   PubMed Web of Science ®Google Scholar
• Pinto ACPN, Piva SR, da Silva Vieira AG, et al. Transcranial direct current stimulation for fatigue in patients with sjogren’s syndrome: a randomized, double-blind pilot study. Brain Stimulation. 2021;14(1):141–151. DOI:10.1016/j.brs.2020.12.004
   PubMed Web of Science ®Google Scholar
• Kedor C, Zernicke J, Hagemann A, et al. A phase II investigator-initiated pilot study with low-dose cyclosporine a for the treatment of articular involvement in primary sjögren’s syndrome. Clin Rheumatol. 2016;35(9):2203–2210. DOI:10.1007/s10067-016-3360-4
   PubMed Web of Science ®Google Scholar
• Luo J, Ming B, Zhang C, et al. IL-2 inhibition of th17 generation rather than induction of treg cells is impaired in primary sjögren’s syndrome patients. Front Immunol. 2018;9:1755.
   PubMed Web of Science ®Google Scholar
• He J, Chen J, Miao M, et al. Efficacy and safety of low-dose interleukin 2 for primary sjögren syndrome: a randomized clinical trial. JAMA Netw Open. 2022;5(11):e2241451. DOI:10.1001/jamanetworkopen.2022.41451
   PubMed Web of Science ®Google Scholar
• Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis. Drugs. 2021;81(9):985–1002.
   PubMed Web of Science ®Google Scholar
• Zaheer M, Wang C, Bian F, et al. Protective role of commensal bacteria in sjögren syndrome. J Autoimmun. 2018;93:45–56.
   PubMed Web of Science ®Google Scholar
• Seror R, Gottenberg JE, Devauchelle-Pensec V, et al. European league against rheumatism sjögren’s syndrome disease activity index and european league against rheumatism sjögren’s syndrome patient-reported index: a complete picture of primary sjögren’s syndrome patients. Arthritis Care Res (Hoboken). 2013 Aug;65(8):1358–1364.
   PubMed Web of Science ®Google Scholar
• James K, Al-Ali S, Tarn J, et al. A transcriptional signature of fatigue derived from patients with primary sjögren’s syndrome. PLoS ONE. 2015;10(12):e0143970. DOI:10.1371/journal.pone.0143970
   PubMed Web of Science ®Google Scholar
• Mariette X, Criswell LA. Primary sjögren’s syndrome. N Engl J Med. 2018;378(10):931–939.
   PubMed Web of Science ®Google Scholar
• Brito-Zeron P, Baldini C, Bootsma H, et al. Sjögren syndrome. Nat Rev Dis Primers. 2016;2(1):1–20. DOI:10.1038/nrdp.2016.47
   Google Scholar
• Beuerman RW, Mircheff A, Pflugfelder SC, et al. The lacrimal functional unit. dry eye and ocular surface disorders. (NY): Marcel Dekker; 2004. p. 11–39.
   Google Scholar
• Fox RI, Stern M. Sjögren’s syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol. 2002;31(2):3–13.
   Google Scholar
• Friedman DI. New frontiers in the treatment and prevention of migraine: a closer look at the role of emerging GCRP targeted therapies. J Man Care Med. 2019;22(2):13–19.
   Google Scholar
• Dolgin E. FDA go-ahead for myasthenia gravis agent. Biotechnol. 2022 Jan;40(1):4. DOI:10.1038/s41587-021-01198-7
   Google Scholar
• Steinfeld S editor. Effects of TNF blockade with infliximab in patients with primary sjogren’s syndrome: an open pilot study. European League Against Rheumatism (EULAR)/European Congress of Rheumatology: Prague Czech Republic. Jun 13-16. 2001.
   Google Scholar
• Steinfeld SD, Demols P, Salmon I, et al. Notice of retraction of two articles (“infliximab in patients with primary sjögren’s syndrome: apilot study” and “infliximab in patients with primary sjögren’s syndrome: one‐year followup”). Arthritis Rheum. 2013 Mar;65(3):814.
   PubMedGoogle Scholar
• Price E. Biologics in sjogren’s syndrome. In: Jain, N., Duggal, L, editors. Handbook of biologics for rheumatological disorders. Springer; 2022. p. 75–84. https://doi.org/10.1007/978-981-16-7200-2_7
   Google Scholar
• Mariette X, Ravaud P, Steinfeld S, et al. editors. Infliximab in primary sjogren’s syndrome: open extension 2 of the TRIPSS study in 64 patients. In Arthritis and rheumatism. 2004. WILEY. WILEYLISS DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
   Google Scholar
• Moutsopoulos NM, Katsifis GE, Angelov N, et al. Lack of efficacy of etanercept in sjogren syndrome correlates with failed suppression of tumour necrosis factor and systemic immune activation. Ann Rheumatic Dis. 2008;67(10):1437–1443. DOI:10.1136/ard.2007.077891
   PubMed Web of Science ®Google Scholar
• van der Heijden EHM, Blokland SLM, Hillen MR, et al. Leflunomide–hydroxychloroquine combination therapy in patients with primary sjögren’s syndrome (repurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. Lancet Rheumatol. 2020;2(5):e260–269. DOI:10.1016/S2665-9913(20)30057-6
   Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary sjögren syndrome with rituximab a randomized trial [article]. Ann Intern Med. 2014;160(4):233–242. DOI:10.7326/M13-1085
   PubMed Web of Science ®Google Scholar
• Chu LL, Cui K, Pope JE. Meta‐analysis of treatment for primary sjögren’s syndrome. Arthritis Care Res. 2020;72(7):1011–1021.
   Web of Science ®Google Scholar
• Silverman GJ, Boyle DL. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti‐CD20 therapy: the b‐cell roadblock hypothesis. Immunol Rev. 2008;223(1):175–185.
   PubMedGoogle Scholar
• Chen M-H, Chen C-K, Chou H-P, et al. Rituximab therapy in primary sjögren’s syndrome with interstitial lung disease: a retrospective cohort study. Clin Exp Rheumatol. 2016;34(6):1077–1084.
   PubMed Web of Science ®Google Scholar
• Smolen J, Nash P, Tahir H, et al. Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients [abstract]. Arthritis rheumatol. 2019;71:(suppl 10). https://acrabstracts.org/abstract/ianalumab-vay736-a-dual-mode-of-action-biologic-combining-baff-receptor-inhibition-with-b-cell-depletion-for-treatment-of-primary-sjogrens-syndrome-results-of-an-international-randomized/. Accessed May 3.
   PubMedGoogle Scholar
• Dörner T, Bowman S, Fox R, et al. POS0692 IANALUMAB (VAY736) SAFETY and EFFICACY in PATIENTS with SJOGREN’S SYNDROME: 52 WEEK RESULTS from a RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL. BMJ Publishing Group Ltd; 2021.
   Google Scholar
• Arbitman L, Furie R, Vashistha H. B cell-targeted therapies in systemic lupuserythematosus. J Autoimmun. 2022;102873. DOI:10.1016/j.jaut.2022.102873
   PubMed Web of Science ®Google Scholar
• Xu D, Zhang S, Huang C, et al. Efficacy and safety of telitacicept in primary sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. ACR AnnualConference; Philadelphia PA, 2022
   Google Scholar
• Dhillon S. Telitacicept: first approval. Drugs. 2021;81(14):1671–1675.
   PubMed Web of Science ®Google Scholar
• van Nimwegen JF, Mossel E, van Zuiden GS, et al. Abatacept treatment for patients with early active primary sjögren’s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). Lancet Rheumatol. 2020;2(3):e153–163. DOI:10.1016/S2665-9913(19)30160-2
   PubMedGoogle Scholar
• Xu H, Li X, Liu D, et al. Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility. Nature. 2013 Apr 25;496(7446):523–527. DOI:10.1038/nature12058
   PubMed Web of Science ®Google Scholar
• Posada J, Valadkhan S, Burge D, et al. Improvement of severe fatigue following nuclease therapy in patients with primary sjögren’s syndrome: a randomized clinical trial. Arthritis Rheumatol. 2020 Aug 15;73(1):143–150. DOI:10.1002/art.41489
   PubMed Web of Science ®Google Scholar
• Driedonks TA, Nolte-‘t Hoen EN. Circulating Y-RNAs in extracellular vesicles and ribonucleoprotein complexes; implications for the immune system. Front Immunol. 2019;9:3164.
   PubMed Web of Science ®Google Scholar
• Katze MG, Fornek JL, Palermo RE, et al. Innate immune modulation by RNA viruses: emerging insights from functional genomics. Nat Rev Immunol. 2008;8(8):644–654. DOI:10.1038/nri2377
   PubMed Web of Science ®Google Scholar
• Nocturne G, Mariette X. Interferon signature in systemic autoimmune diseases: what does it mean? BMJ Specialist J. 2022;8(2):e002687.
   Google Scholar
• Zhang X, Miao M, Zhang R, et al. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2022;7(1):1–8. DOI:10.1038/s41392-022-00887-2
   PubMed Web of Science ®Google Scholar
• Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011 Dec 1;365(22):2067–2077. DOI:10.1056/NEJMoa1105143
   PubMed Web of Science ®Google Scholar
• He J, Zhang X, Wei Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016 Sep;22(9):991–993.
   PubMed Web of Science ®Google Scholar
• Miao M, Hao Z, Guo Y, et al. Short-term and low-dose IL-2 therapy restores the th17/treg balance in the peripheral blood of patients with primary sjögren’s syndrome. Ann Rheumatic Dis. 2018;77(12):1838–1840. DOI:10.1136/annrheumdis-2018-213036
   PubMed Web of Science ®Google Scholar
• Graßhoff H, Comdühr S, Monne LR, et al. Low-dose IL-2 therapy in autoimmune and rheumatic diseases. Front Immunol. 2021;12:648408.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Vizcaya A, Fasano S, Isenberg DA. Bruton’s tyrosine kinase inhibitors: a new therapeutic target for the treatment of SLE? Immunotargets Ther. 2020;9:105.
   PubMed Web of Science ®Google Scholar
• Bruton OC. Agammaglobulinemia. Pediatrics. 1952 Jun;9(6):722–728.
   PubMed Web of Science ®Google Scholar
• Corneth OB, de Bruijn MJ, Rip J, et al. Enhanced expression of bruton’s tyrosine kinase in B cells drives systemic autoimmunity by disrupting T cell homeostasis. J Immunol. 2016 Jul 1;197(1):58–67. DOI:10.4049/jimmunol.1600208
   PubMed Web of Science ®Google Scholar
• Nicolson PLR, Hughes CE, Watson S, et al. Inhibition of btk by btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI. Haematologica. 2018 Dec;103(12):2097–2108.
   PubMed Web of Science ®Google Scholar
• Kaul M, End P, Cabanski M, et al. Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci. 2021;14(5):1756–1768. DOI:10.1111/cts.13005
   PubMed Web of Science ®Google Scholar
• Strand V, O’Quinn S, Furie RA, et al. Clinical meaningfulness of a british isles lupus assessment group-based composite lupus assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. Lancet Rheumatol. 2022;4(3):e198–207.
   Google Scholar
• Chaussabel D, Quinn C, Shen J, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity. 2008 Jul 18;29(1):150–164. DOI:10.1016/j.immuni.2008.05.012
   PubMed Web of Science ®Google Scholar
• Bodewes IL, Björk A, Versnel MA, et al. Innate immunity and interferons in the pathogenesis of sjögren’s syndrome. Rheumatology. 2021;60(6):2561–2573. DOI:10.1093/rheumatology/key360
   PubMed Web of Science ®Google Scholar
• Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in sjogren’s syndrome pathogenesis: contributions in distinct clinical phenotypes and sjogren’s related lymphomagenesis. J Autoimmun. 2015;63:47–58.
   PubMed Web of Science ®Google Scholar
• Seguier J, Jouve E, Bobot M, et al. Paradoxical association between blood modular interferon signatures and quality of life in patients with systemic lupus erythematosus, Rheumatology, Volume 59, Issue 8, August 2020. https://doi.org/10.1093/rheumatology/kez541
   Google Scholar
• Chiche L, Seguier J, Gentile S, et al., editors. Unexpected association between health-related quality of life and the blood interferon modular transcriptional signatures in patients with systemic lupus erythematosus. 2018 ACR/ARHP Annual Meeting; 2018.
   Google Scholar
• Bentley D, Fisher BA, Barone F, et al. A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary sjögren’s syndrome. Rheumatology (Oxford). 2023 Mar 2. DOI:10.1093/rheumatology/kead092
   Web of Science ®Google Scholar
• Levavi H, Lancman G, Gabrilove J. Impact of rituximab on COVID-19 outcomes. Ann Hematol. 2021;100(11):2805–2812.
   PubMed Web of Science ®Google Scholar
• Bacman S, Berra A, Sterin-Borda L, et al. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye sjogren syndrome. Invest Ophthalmol Visual Sci. 2001;42(2):321–327.
   PubMed Web of Science ®Google Scholar
• Goebeler M, Bata‐Csörgő Z, De Simone C, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial. Br J Dermatol. 2022;186(3):429–439. DOI:10.1111/bjd.20782
   PubMed Web of Science ®Google Scholar
• Lünemann JD. Getting specific: targeting fc receptors in myasthenia gravis. Nat Rev Neurol. 2021;17(10):597–598.
   PubMed Web of Science ®Google Scholar
• Nelke C, Spatola M, Schroeter CB, et al. Neonatal fc receptor–Targeted therapies in neurology. Neurotherapeutics. 2022;19(3):1–12. DOI:10.1007/s13311-021-01175-7
   PubMed Web of Science ®Google Scholar